Active Ingredient History
Parathyroid hormone (PTH) is an 84-amino acid peptide that regulates the function of osteoblasts and osteocytes and is secreted by the parathyroid gland in response to changes in the concentration of extracellular calcium. Parathyroid hormone is approved under the brand name NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. It is also available for treatment of postmenopausal osteoporosis in many European countries. Parathyroid hormone is an activator of parathyroid hormone 2 receptor. In addition, was shown, that downregulation of Notch in osteoblasts and osteocytes may represent a mechanism contributing to the anabolic effects of parathyroid hormone in bone. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Aplastic (Phase 2)
Back Pain (Phase 4)
Bone Diseases, Endocrine (Phase 1)
Endocrine System Diseases (Phase 3)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 2)
Hyperparathyroidism (Phase 1)
Hypocalcemia (Early Phase 1)
Hypoparathyroidism (Phase 4)
Hypothyroidism (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lymphoma (Phase 2)
Neoplasms (Phase 1)
Osteopetrosis (Phase 1)
Osteoporosis (Phase 4)
Osteoporosis, Postmenopausal (Phase 2)
Parathyroid Diseases (Phase 3)
Primary Myelofibrosis (Phase 2)
Psoriasis (Phase 1/Phase 2)
Shoulder Fractures (Phase 4)
Sternum (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
